PubMed Health⌕ Search

PubMed · 730650

Microcrystalline identification test of some amphetamines and hydrochlorothiazide: collaborative study.

Abstract

A previously described procedure for the identification of methamphetamine, dl-deoxyephedrine, dextroamphetamine, and amphetamine and a new procedure for hydrochlorothiazide identification have been subjected to collaborative study. The method for the amphetamines depends upon their volatilization from a strongly basic solution into a hanging drop containing gold chloride and the formation of characteristic crystals. The hydrochlorothiazide method is direct: the I2-KI solution is added to an alkaline solution of hydrochlorothiazide to cause the deposition of characteristic crystals. Of the 40 unknown drug dosage form powders supplied to 10 collaborators, 39 were correctly identified. The results indicate that the amphetamine procedure is capable of distinguishing between methampetamine and dl-deoxyephedrine. The age of the gold chloride reagent is important in these tests. The official final action tests for dl-deoxyephedrine and methampetamine were modified and Table 36:04 has been revised to reflect these changes. The hydrochlorothiazide test has been adopted as official first action and added to Table 36:05.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Auerbach. 1978. Microcrystalline identification test of some amphetamines and hydrochlorothiazide: collaborative study.. https://pubmed.ncbi.nlm.nih.gov/730650/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

New insights into the mechanism of action of amphetamines.

Amphetamine is a psychostimulant commonly used to treat several disorders, including attention deficit, narcolepsy, and obesity. Plasmalemmal and vesicular monoamine transporters, such as the neuronal dopamine transporter and the vesicular monoamine transporter-2, are two of its principal targets. This review focuses on new insights, obtained from both in vivo and in vitro studies, into the molecular mechanisms whereby amphetamine, and the closely related compounds methamphetamine and methylenedioxymethamphetamine, cause monoamine, and particularly dopamine, release. These mechanisms include amphetamine-induced exchange diffusion, reverse transport, and channel-like transport phenomena as well as the weak base properties of amphetamine. Additionally, amphetamine analogs may affect monoamine transporters through phosphorylation, transporter trafficking, and the production of reactive oxygen and nitrogen species. All of these mechanisms have potential implications for both amphetamine- and methamphetamine-induced neurotoxicity, as well as dopaminergic neurodegenerative diseases.

Amphetamines↗

Effect of GABAergic ligands on the anxiolytic-like activity of DOI (a 5-HT(2A/2C) agonist) in the four-plate test in mice.

5-HTergic and GABAergic systems are involved in neurobiology of anxiety. Precedent studies have demonstrated that SSRIs possessed an anxiolytic-like effect in the four-plate test (FPT) at doses that did not modify spontaneous locomotor activity. This effect seems to be mediated through the activation of 5-HT(2A) postsynaptic receptors. The purpose of the present study was to examine the implication of GABA system in the anxiolytic-like activity of DOI in the FPT. To achieve this, the co-administration of DOI (5-HT(2A/2C) receptor agonists) with GABA(A) and GABA(B) receptor ligands was evaluated in the FPT. Alprazolam, diazepam and muscimol (for higher dose) potentiated the anxiolytic-like effect of DOI. Bicuculline, picrotoxin and baclofen inhibited the anxiolytic-like effect of DOI. Flumazenil and CGP 35348 had no effect on the anxiolytic-like activity of DOI. These results suggest that the GABA system seems to be strongly implicated in the anxiolytic-like activity of DOI in the FPT.

Amphetamines↗